Choksi laboratories Limited has announced the reconstitution of its key board committees following changes in director composition, effective February 07, 2026. The pharmaceutical company informed BSE Limited about these structural changes in compliance with SEBI listing regulations.

Director Changes Drive Committee Restructuring

The reconstitution became necessary after Mrs. Meenaxi Patidar (DIN: 10206356) ceased to be a Non-Executive Independent Director on January 09, 2026, following her resignation from the position. Her departure resulted in her automatic cessation from all board committees of the company.

To fill the vacancy, the Board of Directors approved the appointment of Mr. Ritik Pavecha (DIN: 08790431) as an additional director in the category of Non-Executive Independent Director during their meeting on February 07, 2026. This appointment remains subject to approval from shareholders.

Reconstituted Committee Compositions

The company has restructured three critical committees to ensure compliance with regulatory requirements under Sections 177 and 178 of the Companies Act, 2013, and SEBI listing regulations.

Audit Committee

Nomination and Remuneration Committee

Stakeholders' Relationship Committee

Regulatory Compliance

The reconstitution ensures adherence to Regulations 18, 19, and 21 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. All three committees now maintain the required composition of independent directors as mandated by regulatory frameworks.

The company secretary and compliance officer, Prakhar Dubey, signed the regulatory filing digitally, confirming the formal communication to BSE Limited regarding these governance changes. The restructured committees became effective immediately from February 07, 2026.

Choksi Laboratories Limited has officially submitted its unaudited financial results for the third quarter of FY26 ended December 31, 2025, to BSE Limited under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The analytical testing and calibration laboratory group demonstrated strong operational performance with significant improvements across key financial metrics, alongside strategic board changes approved during the meeting held on February 7, 2026.

Financial Performance Overview

The company's Q3FY26 results showed remarkable improvement compared to the corresponding period in the previous year, with net profit witnessing exceptional growth:

For the nine-month period ended December 31, 2025, the company reported revenue from operations of ₹3,318.37 lakhs compared to ₹3,038.28 lakhs in the corresponding nine-month period of FY25, representing a growth of 9.22%. The nine-month net profit increased substantially to ₹93.75 lakhs from ₹60.20 lakhs in the previous year.

Exceptional Item and Income Components

During Q3FY26, Choksi Laboratories recorded an exceptional gain of ₹77.80 lakhs from the sale of an office flat. This non-recurring transaction was classified as an exceptional item as it does not form part of the company's ordinary operating activities. Other income for the quarter totaled ₹13.34 lakhs, comprising interest income of ₹0.58 lakhs, interest on IT refund of ₹13.26 lakhs, cash back on credit card of ₹0.21 lakhs, and forex gain of ₹1.10 lakhs.

Board Leadership Changes

The board meeting resulted in significant leadership transitions that will shape the company's governance structure:

Mr. Ritik Pavecha brings qualified expertise in audit, assurance, corporate compliance, governance, and regulatory advisory. The company affirmed that he is not debarred from holding directorship by SEBI or any other authority and holds no equity shares in the company.

Regulatory Compliance and Audit

The financial results were duly reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on February 7, 2026. The results were prepared in accordance with Indian Accounting Standards (Ind AS) notified under Section 133 of the Companies Act, 2013. Prateek Jain & Co., Chartered Accountants (FRN-009494C), provided the independent auditor's review report, confirming that the results comply with applicable recognition and measurement principles and disclosure requirements under listing regulations.

Operational Metrics

Choksi Laboratories continues to operate under a single business segment of "Analysis and Testing" as per Ind AS 108 Operating Segments. The company's total expenses for Q3FY26 were ₹1,083.23 lakhs compared to ₹1,021.02 lakhs in Q3FY25. Key expense components included employee benefits expense of ₹454.10 lakhs, other expenses of ₹183.39 lakhs, and power & fuel charges of ₹130.44 lakhs. The meeting commenced at 12:30 PM and concluded at 2:35 PM at the company's registered office in Indore, Madhya Pradesh.

Source: